Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
Withdrawn before enrolling · Phase 2 · Has a placebo group
Conditions studied: COVID19
In brief
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Key facts
- Study ID
- NCT04338126
- Run by
- University of Alabama at Birmingham
- People needed
- 0
- Starts
- 2021-09-30
- Expected to finish
- 2021-12-31
- Last updated by the study team
- 2021-04-23
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Positive COVID19 test
- Admission to hospital without immediate plans for Intensive Care Unit transfer
- Age >/= 19 y.o.
You may not qualify if…
- Allergic reaction to tranexamic acid
- History or active evidence of hypercoagulation disorders including but not limited to deep vein thrombosis, pulmonary hypertension, diffuse intravascular coagulopathy
- Preadmission anticoagulation
- History of GI bleeding
- History of seizures
- Cardiac or other vascular stents
- History of severe renal disease
- History of intracranial hemorrhage
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.